The federal landscape for cannabis and hemp regulations is currently undergoing a massive stress test. As various government agencies attempt to navigate the complex web of cannabinoid legality, industry leaders are pushing for clarity, consistency, and a more logical approach to policy enforcement.
Recently, the White House took a step toward addressing these issues by holding the first in a series of scheduled meetings with key cannabis industry stakeholders.
This initial meeting, hosted by the Office of Information and Regulatory Affairs (OIRA) under the White House Office of Management and Budget (OMB), focused heavily on a proposed new enforcement policy for CBD products from the Food and Drug Administration (FDA).
As originally reported by Marijuana Moment, the first industry representative to secure an audience was David Heldreth, CEO of Panacea Plant Sciences.
The Problem of Conflicting Agency Policies
One of the most significant takeaways from the meeting is the apparent disconnect between different federal agencies. The federal government recently launched a Centers for Medicare & Medicaid Services (CMS) initiative designed to cover certain hemp-derived CBD and THC products. While this seems like a massive win for cannabis accessibility, Heldreth pointed out a glaring legal contradiction to the OIRA and FDA representatives present.
As Heldreth told Marijuana Moment, “Current FDA policy is that CBD can’t be a [generally recognized as safe], food additive or supplement, and as such technically all CBD products are illegal outside vaping and smoking.”
He explained to the officials that the government had essentially “put the cart before the horse.” Reimbursing patients for CBD products through Medicare and Medicaid creates an incredible legal paradox when the FDA still classifies those exact products as illegal food additives.
Expanding on Heldreth’s observation, this contradiction leaves businesses in a highly vulnerable position. If a company produces a CBD tincture, they might find a willing partner in the CMS reimbursement program, yet still face the threat of FDA enforcement actions for selling an unapproved supplement.
Harmonizing these policies is an absolute necessity to prevent a chaotic, legally perilous environment for business owners and patients alike.
Expanding the Scope Beyond CBD Isolate
Another critical element of the discussion centered on how the FDA should classify various parts of the hemp plant. Discussions about cannabis policy often hyper-focus on specific cannabinoids, particularly isolated CBD or Delta-9 THC. Heldreth pushed the federal officials to broaden their perspective and acknowledge the legal nuances of the plant’s raw materials.
He highlighted to Marijuana Moment that recent federal legislation created specific limits for cannabinoid extracts, but maintained distinct carve-outs for industrial hemp. He argued that the FDA’s policy should explicitly define hemp leaves and microgreens as food and permit them as food additives. To build upon Heldreth’s argument, acknowledging the whole plant presents several distinct advantages for the industry:
- Diversified product lines: Allowing hemp leaves and microgreens as food additives would open the door for nutrient-dense salads, teas, and functional food products that utilize the plant without relying heavily on chemical extraction.
- Reduced regulatory friction: Whole plant materials that naturally fall below the 0.3 percent THC threshold are easier to regulate as traditional agricultural products compared to highly concentrated, synthesized isolates.
- Economic relief for farmers: Providing a clear, legal avenue for farmers to sell their hemp leaves to the food industry would significantly reduce agricultural waste and create entirely new revenue streams.
By recognizing the natural form of the plant as a food source, the FDA could bypass much of the complex pharmacological debate surrounding isolated cannabinoids.
The Unavoidable Need for Congressional Action
Despite having the floor to present these arguments to the White House, expectations for immediate, sweeping change remain low. The FDA representatives at the meeting reportedly declined to provide any details about their upcoming policy or a timeline for its release. Heldreth himself expressed skepticism about the immediate impact of the discussion.
“I’m glad the White House held the meeting, but I believe this whole process won’t amount to much,” he told Marijuana Moment, pointing out that he had participated in similar discussions back in 2020 with no tangible results.
The core barrier preventing meaningful progress is the federal drug preclusion law. The law prohibits marketing an active ingredient in an approved prescription drug as a dietary supplement or adding it to food. Because the FDA approved CBD as the active ingredient in the epilepsy medication Epidiolex, the agency maintains it cannot act.
“The reality is without congressional action to address the drug preclusion law it’s difficult to get CBD allowed,” Heldreth stated.
Expanding on this reality, the cannabis industry must redirect a significant portion of its advocacy efforts toward lawmakers rather than solely focusing on agency bureaucrats. Until Congress passes legislation that explicitly exempts hemp-derived cannabinoids from the drug preclusion clause, the FDA will likely continue to operate in a state of regulatory paralysis.
Preparing for the Road Ahead
The insights from this first White House meeting offer a sobering but necessary perspective for anyone involved in the CBD space. Federal agencies are actively trying to piece together a coherent enforcement strategy, but they are doing so within a fractured legal framework.
For now, companies should closely monitor the CMS pilot program and the looming FDA enforcement policy. They should also consider Heldreth’s strategy of looking toward raw hemp materials—like leaves and microgreens—that may fall outside the strict pharmacological definitions restricting CBD extracts. Most importantly, the industry must recognize that true, permanent relief will only arrive through decisive congressional legislation.
Frequently Asked Questions (FAQ)
The Office of Information and Regulatory Affairs (OIRA) held the meeting to gather stakeholder input on a proposed, yet-to-be-published FDA enforcement policy regarding CBD products.
The first meeting was attended by representatives from OIRA, unidentified members of the FDA, and David Heldreth, the CEO of Panacea Plant Sciences.
He pointed out the legal contradiction of a new CMS initiative offering Medicare/Medicaid reimbursement for CBD products while current FDA policy still considers most CB
Due to the federal drug preclusion law, the FDA states it cannot regulate CBD as a dietary supplement because it is already approved as an active ingredient in a prescription drug. Congress must pass new legislation to create a legal exemption for hemp-derived CBD.
